The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 3, 2005, Pages 285-293

  Karmazin, Alexander ^a   Moore, Wayne V ^a   Popovic, Jadranka ^a   Jacobson, Jill D ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Aromatase inhibitors; Bone age progression; Letrozole

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; CORTICOTROPIN; GROWTH HORMONE; LETROZOLE; OXANDROLONE; TESTOSTERONE;

ADOLESCENT; ADRENAL FUNCTION; ADRENAL SUPPRESSION; ADULT; ARTICLE; BODY HEIGHT; BONE AGE; BONE GROWTH; BONE MATURATION; BONE RADIOGRAPHY; CLINICAL ARTICLE; CORTICOTROPIN TEST; DECELERATION; DELAYED PUBERTY; DISEASE SEVERITY; DRUG EFFICACY; GROWTH HORMONE DEFICIENCY; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; PREDICTION; SHORT STATURE; STATISTICAL ANALYSIS;

EID: 15844390294     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.3.285     Document Type: Article

References (17)

1. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-3698.
2. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357: 1743-1748.
3. Hagenas L. Growth rate can be manipulated. Estrogen production in pubertal boys can be blocked by an aromatase inhibitor. Lakartidningen 2002; 99: 165-168.
4. Michaud L, Buzdar A. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999; 21: 297-309.
5. Lamberts SW, Bruining HA, Marzouk H, Zuiderwijk J, Uitterlinden P, Blijd JJ, Hackeng WH, De Jong FH. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 1999; 69: 896-901.
6. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L, Martinetti A, Marchiano A, Pozzi P, Stani S, Bichisao E. Double-blind, randomized, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999; 35: 208-213.
7. Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N. Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol 2000; 52: 633-640.
8. Park Y, Park K, Kim J, Shin C, Kim S, Lee H. Reproducibility of the cortisol response to stimulation with the low dose (1 microg) of ACTH. Clin Endocrinol 1999; 51: 153-158.
9. Weintrob N, Sprecher E, Josefsberg Z, Vardi P, Weininger C, Aurbach-Klipper Y, Pertzelan A, Phillip M. Combined clonidine-short-ACTH test for the simultaneous assessment of growth hormone reserve and hypothalamic-pituitary-adrenal axis integrity in children. Eur J Endocrinol 2000; 143: 105-110.
10. Agwu JC, Spoudeas H, Hindmarsh PC, Pringle PJ, Brook CG. Tests of adrenal insufficiency. Arch Dis Child 1999; 80: 330-333.
11. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40: 423-441.
12. Goss PE, Tye LM. Anastrozole: a new selective non-steroidal aromatase inhibitor. Oncology 1997; 11: 1697-1703.
13. Santen R, Harvey H. Use of aromatase inhibitors in breast carcinoma. Endocr Related Cancer 1999; 6: 75-92.
14. Ragaz J. Status of aromatase inhibitors in relation to other breast cancer treatment modalities. Endocr Related Cancer 1999; 6: 277-291.
15. Bisagni G, Cocconi G, Scaglione F, Fraschini F, Psister C, Trunet P. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996; 7: 99-102.
16. Yanovski J, Rose S, Municchi G, Pescovitz O, Hill S, Cassorla F, Cutler GB Jr. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003; 348: 908-917.
17. Mauras N, O'Brien K, Klein K, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000; 85: 2370-2377.